“Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s258. Accessed May 22, 2026. https://skin.dermsquared.com/skin/article/view/2428.